BOSTON, Oct. 3 /PRNewswire/ -- Surface Logix, Inc. announced that Jim
Mahoney, President and Chief Executive Officer, will present an update of
the company's drug development pipeline at the 2007 BIO Investor Forum on
October 10, 2007 at 1:45 PM PST from The Palace Hotel in San Francisco.
Surface Logix currently has two programs in human clinical trials with
a third program approaching an IND filing. Mr. Mahoney will discuss the
latest results for SLx-2101 and SLx-4090. SLx-2101, a second generation
PDE5 inhibitor designed to address cardiovascular indications, is currently
in two separate Phase 2a trials, one in hypertension and the other in
Raynaud's Syndrome. SLx-4090, a first-in-class enterocyte specific MTP
inhibitor for the treatment of dyslipidemia and potentially other
indications, will soon be completing a Phase 2a study.
About Surface Logix, Inc.
Surface Logix, Inc. uses its expertise in biophysical chemistry to
create and develop novel small molecule drugs (NCEs) with superior
intrinsic drug- like properties that are clearly differentiated from
competitive products. The company is advancing multiple internal programs
focused primarily on cardiovascular, metabolic, inflammatory and fibrotic
diseases. For more information, please visit http://www.surfacelogix.com.
Contact:
Leland Webster, Ph.D., M.B.A.
Surface Logix Inc.
Vice President, Corporate Development
617.746.8520
Media:
Sarah Cavanaugh
MacDougall Biomedical Communications, Inc.
scavanaugh@macbiocom.com
508.647.0209
SOURCE Surface Logix, Inc.
 back to top
Related links:
http://www.surfacelogix.com
CONTACT:
Leland Webster, Ph.D., M.B.A. of Surface
Logix Inc., Vice President, Corporate Development,
+1-617-746-8520; or Media: Sarah Cavanaugh of MacDougall
Biomedical Communications, Inc. for Surface Logix Inc., +1-508-
647-0209, scavanaugh@macbiocom.com
|
